Rose City Young Marines of Tyler win national DEA award
Tips for Texas Motor Speedway attendees: Parking, schedule and more
Young Marines is a youth education and services program for boys and girls that promotes the mental, moral and physical development of its members, according to their website. The Young Marines won the Division 4 Enrique 'Kiki' Camarena Award given by the Drug Enforcement Administration for drug demand reduction efforts through community education and peer-to-peer role modeling, a press release said.
This award is named in honor of DEA Special Agent and U.S. Marine Enrique 'Kiki' Camarena who was abducted and murdered while working to expose top leaders of a major drug pipeline in 1985. To win this award, Young Marine units are judged on drug demand reduction hours, their curriculum and the steps they take to include community members and other organizations.
'These Young Marines represent the kind of leadership and courage we need in the fight against dangerous and deadly drugs,' DEA Acting Administrator Derek S. Maltz said. 'Their commitment to prevention and education sends a powerful message to their peers. They're not just talking about a drug-free future, they're working to build one.'
Kilgore student earns historic recognition for her skills in welding
One aspect of the Young Marines program is living a healthy, drug-free lifestyle while encouraging those not in the program to do the same. Members must teach standardized curriculum that informs people about gateway drugs and drugs that currently effect the youth.
'The impact of fentanyl and other dangerous drugs continues to devastate families across the country,' Col. William P. Davis USMC (Ret), national executive director and CEO of the Young Marines said. 'Our Young Marines are answering that challenge with purpose and creativity. These award-winning units show what's possible when young leaders take action for the good of their communities.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
DEA Scrambles to Defend Marijuana Decision Amid Supreme Court Ruling, Legal Collapse And Public Outrage
"This Wasn't DEA Marijuana Regulation - It Was a DEA Illegal Ambush." ALL EYES ON TERRY COLE!MMJ BioPharma Cultivation CEO Duane Boise is calling out the DEA's desperate attempt to defend a marijuana Administrative Law Judge decision that never got a hearing, blocked marijuana scientific evidence, and defied Supreme Court precedent. "They're defending a hearing that never actually happened," said Duane Boise."We followed every rule. They followed none." WASHINGTON, D.C. / / July 27, 2025 / Friday, the U.S. Drug Enforcement Administration (DEA) filed a last-minute response in an escalating legal battle with MMJ BioPharma Cultivation, a Rhode Island-based pharmaceutical company seeking to grow federally compliant cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. The agency's filing comes in response to MMJ's official legal "exceptions" challenging a controversial ruling by DEA Chief Administrative Law Judge John Mulrooney II (aka Mclooney) - a ruling that denied MMJ's bulk manufacturing registration without a hearing, without cross-examination, and without admitting material evidence into the record. "We were stonewalled at every step," said Duane Boise, CEO of MMJ BioPharma. "The DEA ignored Supreme Court precedent, blocked our science, and manipulated the process to produce a predetermined outcome. Now they're trying to defend that decision in a system the Department of Justice itself has declared unconstitutional." Constitutional Crisis MMJ's case has become a flashpoint in the broader collapse of the DEA's internal court system. In Axon v. FTC (2023) and Jarkesy v. SEC (2024), the U.S. Supreme Court ruled that agency administrative law judges (ALJs) violate the separation of powers because they are insulated from presidential removal - a direct hit to the DEA's current process. Even the Department of Justice has abandoned its defense of the ALJ structure, and Attorney General Pam Bondi notified the courts in February 2025 that DEA hearings like the one against MMJ BioPharma Cultivation are legally void. DEA's Desperate Defense Despite this, the DEA has now used its one allotted legal filing to respond to MMJ's exceptions - an effort seen by legal experts as a last-ditch attempt to salvage a crumbling decision and maintain bureaucratic control over cannabis based drug development. "This is the DEA doubling down on injustice," said Boise. "They're defending a hearing that never actually happened because they're afraid of what the truth will show." A Legitimate Researcher, Blocked MMJ BioPharma Cultivation is not a dispensary. It is a federally compliant manufacturer that has: FDA Orphan Drug Designation Two accepted Investigational New Drug (IND) applications A pharmaceutical grade cannabis facility built to DEA standards Binding supply agreements with Schedule I licensees Yet after more than 2,400 days of delays, the DEA still refuses to approve its registration - while unlicensed tribal and cartel-linked marijuana networks operate with impunity across state lines, and recreational cannabis companies receive preferential treatment. Path Forward: Will Administrator Terrance Cole Act? All eyes now turn to Terrance Cole, President Trump's newly confirmed DEA Administrator, who holds the final authority to approve or deny MMJ's license. "Administrator Cole has a choice," said Boise. "He can defend a broken system riddled with bias and constitutional violations-or he can restore integrity by granting our lawful, science backed registration and ending seven years of obstruction." MMJ BioPharma has vowed to take its case as far as necessary, including seeking federal injunctions and legislative reform if the DEA continues to block research. About MMJ BioPharma Cultivation MMJ BioPharma is a federally compliant biopharmaceutical company focused on producing cannabis derived medicines for neurodegenerative diseases. It operates under FDA regulatory frameworks and maintains partnerships with international GMP manufacturers and licensed U.S. laboratories. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
Associated Press
12 hours ago
- Associated Press
DEA Scrambles to Defend Marijuana Decision Amid Supreme Court Ruling, Legal Collapse And Public Outrage
'This Wasn't DEA Marijuana Regulation - It Was a DEA Illegal Ambush.' ALL EYES ON TERRY COLE! MMJ BioPharma Cultivation CEO Duane Boise is calling out the DEA's desperate attempt to defend a marijuana Administrative Law Judge decision that never got a hearing, blocked marijuana scientific evidence, and defied Supreme Court precedent. ' They're defending a hearing that never actually happened,' said Duane Boise.'We followed every rule. They followed none.' WASHINGTON, D.C. / ACCESS Newswire / July 27, 2025 / Friday, the U.S. Drug Enforcement Administration (DEA) filed a last-minute response in an escalating legal battle with MMJ BioPharma Cultivation, a Rhode Island-based pharmaceutical company seeking to grow federally compliant cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. The agency's filing comes in response to MMJ's official legal 'exceptions' challenging a controversial ruling by DEA Chief Administrative Law Judge John Mulrooney II (aka Mclooney) - a ruling that denied MMJ's bulk manufacturing registration without a hearing, without cross-examination, and without admitting material evidence into the record. 'We were stonewalled at every step,' said Duane Boise, CEO of MMJ BioPharma. 'The DEA ignored Supreme Court precedent, blocked our science, and manipulated the process to produce a predetermined outcome. Now they're trying to defend that decision in a system the Department of Justice itself has declared unconstitutional.' Constitutional Crisis MMJ's case has become a flashpoint in the broader collapse of the DEA's internal court system. In Axon v. FTC (2023) and Jarkesy v. SEC (2024), the U.S. Supreme Court ruled that agency administrative law judges (ALJs) violate the separation of powers because they are insulated from presidential removal - a direct hit to the DEA's current process. Even the Department of Justice has abandoned its defense of the ALJ structure, and Attorney General Pam Bondi notified the courts in February 2025 that DEA hearings like the one against MMJ BioPharma Cultivation are legally void. DEA's Desperate Defense Despite this, the DEA has now used its one allotted legal filing to respond to MMJ's exceptions - an effort seen by legal experts as a last-ditch attempt to salvage a crumbling decision and maintain bureaucratic control over cannabis based drug development. 'This is the DEA doubling down on injustice,' said Boise. 'They're defending a hearing that never actually happened because they're afraid of what the truth will show.' A Legitimate Researcher, Blocked MMJ BioPharma Cultivation is not a dispensary. It is a federally compliant manufacturer that has: Yet after more than 2,400 days of delays, the DEA still refuses to approve its registration - while unlicensed tribal and cartel-linked marijuana networks operate with impunity across state lines, and recreational cannabis companies receive preferential treatment. Path Forward: Will Administrator Terrance Cole Act? All eyes now turn to Terrance Cole, President Trump's newly confirmed DEA Administrator, who holds the final authority to approve or deny MMJ's license. 'Administrator Cole has a choice,' said Boise. 'He can defend a broken system riddled with bias and constitutional violations-or he can restore integrity by granting our lawful, science backed registration and ending seven years of obstruction.' MMJ BioPharma has vowed to take its case as far as necessary, including seeking federal injunctions and legislative reform if the DEA continues to block research. About MMJ BioPharma Cultivation MMJ BioPharma is a federally compliant biopharmaceutical company focused on producing cannabis derived medicines for neurodegenerative diseases. It operates under FDA regulatory frameworks and maintains partnerships with international GMP manufacturers and licensed U.S. laboratories. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Black America Web
2 days ago
- Black America Web
Jeff Teague Walks Back Claim LeBron James Took Steroids During Miami Heat Days, Social Media Reacts
Jeff Teague and his friends-turned-co-host on the Club 520 podcast are known for cracking jokes at the former player's expense and giving hilarious takes and some behind-the-scenes in-game moments. The trio is very unfiltered to say the least, and now Teague may have poked the wrong bear with a recent comment about LeBron James when he was in his prime during his Big Three era with the Miami Heat. He was so dominant those years that Teague joked that he was juicing. 'Miami Heat Bron, he was on steroids bro, he had to sit out because he was on steroids. Allegedly,' Teague said. 'He had to sit out when they started testing for HGH, and he said his back was hurt and sat out for like three weeks and came back skinny. I was in the league, and I remember. He came back, and he was crazy.' The only thing is, it wasn't exactly a joke, because back in 2013, the allegation led to an FBI investigation. The DEA busted Florida's Biogenesis clinic in what became the largest doping operation in U.S. sports history, involving Alex Rodriguez, Nelson Cruz, and WWE star Paul 'The Big Show' Wight. The federal documents consisted of 1,400 pages and included David Alexander, a well-known trainer who had worked with James, as well as the NBA champions' friend and business manager, Ernest 'Randy' Mims, which led to the feds looking into the then Heat star before ultimately clearing him. 'I can tell you that we looked into everything just because we knew this day would come,' the lead DEA investigator concluded, according to ESPN. 'There was never any indication that LeBron James did anything wrong.' Docs do suggest that Mims purchased testosterone — a Schedule III controlled substance — and metabolism-boosting injections, but he claimed they were for himself. Right on time, those proverbial Klutch-branded trucks pulled up on Teague, who issued a clarification on social media. 'Y'all weird I was joking about bron he was just that dominant chill,' he wrote to his Instagram stories. See how social media is reacting to the steroid allegations spinning the block below. Jeff Teague Walks Back Claim LeBron James Took Steroids During Miami Heat Days, Social Media Reacts was originally published on
